{
  "guideline": {
    "id": "PA166182603",
    "name": "Annotation of CPIC Guideline for efavirenz and CYP2B6",
    "source": "CPIC",
    "version": 9,
    "url": "https://www.pharmgkb.org/guidelineAnnotation/PA166182603",
    "relatedChemicals": [
      {
        "id": "PA449441",
        "name": "efavirenz",
        "symbol": null
      }
    ],
    "relatedGenes": [
      {
        "id": "PA123",
        "name": "cytochrome P450 family 2 subfamily B member 6",
        "symbol": "CYP2B6"
      }
    ],
    "recommendation": true
  },
  "recommendations": [
    {
      "id": "PA166297892",
      "name": "Recommendation PA166297892",
      "population": "child >40kg_adult",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060494,
        "html": "<p>Initiate efavirenz with standard dosing (600 mg/day)</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>The ENCORE study showed that in treatment-naïve patients randomized to initiate efavirenz-based regimens (combined with tenofovir and emtricitabine), 400 mg/day was non-inferior to 600 mg/day regardless of CYP2B6 genotype (PMID 24522178).</p>\n"
      },
      "implications": [
        "CYP2B6: Normal efavirenz metabolism"
      ],
      "lookupKey": {
        "CYP2B6": "Normal Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297893",
      "name": "Recommendation PA166297893",
      "population": "child >40kg_adult",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060495,
        "html": "<p>Consider initiating efavirenz with decreased dose of 400 mg/day</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.</p>\n"
      },
      "implications": [
        "CYP2B6: Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; increased risk of CNS adverse events"
      ],
      "lookupKey": {
        "CYP2B6": "Intermediate Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297894",
      "name": "Recommendation PA166297894",
      "population": "child >40kg_adult",
      "classification": {
        "term": "Moderate",
        "termId": "guidelineStrength:981501931"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060496,
        "html": "<p>Consider initiating efavirenz with decreased dose of 400 or 200 mg/day</p>\n<h4 id=\"other-considerations\">Other Considerations</h4>\n<p>If therapeutic drug monitoring is available and a decreased efavirenz dose is prescribed, consider obtaining steady-state plasma efavirenz concentrations to ensure concentrations are in the suggested therapeutic range (~1 to 4 μg/mL). To prescribe efavirenz at a decreased dose of 400 mg/day or 200 mg/day in a multidrug regimen may require prescribing more than one pill once daily. If so, the provider should weigh the potential benefit of reduced dose against the potential detrimental impact of increased pill number.</p>\n"
      },
      "implications": [
        "CYP2B6: Higher dose-adjusted trough concentrations of efavirenz compared with normal metabolizers; significantly increased risk of CNS adverse events and treatment discontinuation"
      ],
      "lookupKey": {
        "CYP2B6": "Poor Metabolizer"
      },
      "dosingInformation": true,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297890",
      "name": "Recommendation PA166297890",
      "population": "child >40kg_adult",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060492,
        "html": "<p>Initiate efavirenz with standard dosing (600 mg/day)</p>\n"
      },
      "implications": [
        "CYP2B6: Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2B6": "Ultrarapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297895",
      "name": "Recommendation PA166297895",
      "population": "child >40kg_adult",
      "classification": {
        "term": "No recommendation",
        "termId": "guidelineStrength:1448526251"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060497,
        "html": "<p>No recommendation</p>\n"
      },
      "implications": [
        "CYP2B6: n/a"
      ],
      "lookupKey": {
        "CYP2B6": "Indeterminate"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    },
    {
      "id": "PA166297891",
      "name": "Recommendation PA166297891",
      "population": "child >40kg_adult",
      "classification": {
        "term": "Strong",
        "termId": "guidelineStrength:981501930"
      },
      "relatedChemicals": [
        {
          "id": "PA449441",
          "name": "efavirenz",
          "symbol": null
        }
      ],
      "text": {
        "id": 1452060493,
        "html": "<p>Initiate efavirenz with standard dosing (600 mg/day)</p>\n"
      },
      "implications": [
        "CYP2B6: Slightly lower dose-adjusted trough concentrations of efavirenz compared with normal metabolizers"
      ],
      "lookupKey": {
        "CYP2B6": "Rapid Metabolizer"
      },
      "dosingInformation": false,
      "alternateDrugAvailable": false,
      "otherPrescribingGuidance": false
    }
  ],
  "citations": [
    {
      "pmid": "31006110",
      "title": "Clinical Pharmacogenetics Implementation Consortium (CPIC) Guideline for CYP2B6 and Efavirenz-Containing Antiretroviral Therapy.",
      "authors": [
        "Desta Zeruesenay",
        "Gammal Roseann S",
        "Gong Li",
        "Whirl-Carrillo Michelle",
        "Gaur Aditya H",
        "Sukasem Chonlaphat",
        "Hockings Jennifer",
        "Myers Alan",
        "Swart Marelize",
        "Tyndale Rachel F",
        "Masimirembwa Collen",
        "Iwuchukwu Otito F",
        "Chirwa Sanika",
        "Lennox Jeffrey",
        "Gaedigk Andrea",
        "Klein Teri E",
        "Haas David W"
      ],
      "journal": "Clinical pharmacology and therapeutics",
      "year": 2019,
      "_sameAs": "https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6739160"
    }
  ],
  "version": "2024-02-29-20-19"
}